Omalizumab (Xolair) treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health [2017]
Materias:
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820427006719
Descripción
Descripción Física:1 online resource (xiii, 75 pages) : illustrations
Bibliografía:Includes bibliographical references.